340 related articles for article (PubMed ID: 12488337)
1. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.
Singleton DW; Feng Y; Burd CJ; Khan SA
Endocrinology; 2003 Jan; 144(1):121-8. PubMed ID: 12488337
[TBL] [Abstract][Full Text] [Related]
2. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
Menendez JA; Oza BP; Atlas E; Verma VA; Mehmi I; Lupu R
Oncogene; 2004 Jun; 23(28):4945-58. PubMed ID: 15094777
[TBL] [Abstract][Full Text] [Related]
4. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells.
Zhang L; Li X; Zhao L; Zhang L; Zhang G; Wang J; Wei L
J Cell Biochem; 2009 Mar; 106(4):553-62. PubMed ID: 19160418
[TBL] [Abstract][Full Text] [Related]
5. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells.
Bhat KP; Pezzuto JM
Cancer Res; 2001 Aug; 61(16):6137-44. PubMed ID: 11507064
[TBL] [Abstract][Full Text] [Related]
7. Cloning and functional characterization of PELP1/MNAR promoter.
Mishra SK; Balasenthil S; Nguyen D; Vadlamudi RK
Gene; 2004 Apr; 330():115-22. PubMed ID: 15087130
[TBL] [Abstract][Full Text] [Related]
8. Role of estrogen receptor ligand and estrogen response element sequence on interaction with chicken ovalbumin upstream promoter transcription factor (COUP-TF).
Klinge CM
J Steroid Biochem Mol Biol; 1999 Nov; 71(1-2):1-19. PubMed ID: 10619353
[TBL] [Abstract][Full Text] [Related]
9. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
11. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
[TBL] [Abstract][Full Text] [Related]
12. Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.
Guzmán CB; Deighton-Collins S; Martinez A; Kleerekoper M; Zhao C; Benjamins JA; Skafar DF
Neuro Endocrinol Lett; 2005 Oct; 26(5):526-32. PubMed ID: 16264406
[TBL] [Abstract][Full Text] [Related]
13. The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells.
Klinge CM; Jernigan SC; Risinger KE
Endocrinology; 2002 Mar; 143(3):853-67. PubMed ID: 11861507
[TBL] [Abstract][Full Text] [Related]
14. An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.
Demirpence E; Semlali A; Oliva J; Balaguer P; Badia E; Duchesne MJ; Nicolas JC; Pons M
Cancer Res; 2002 Nov; 62(22):6519-28. PubMed ID: 12438246
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation.
Duan R; Porter W; Safe S
Endocrinology; 1998 Apr; 139(4):1981-90. PubMed ID: 9528985
[TBL] [Abstract][Full Text] [Related]
16. Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene.
Levy N; Zhao X; Tang H; Jaffe RB; Speed TP; Leitman DC
Endocrinology; 2007 Jul; 148(7):3449-58. PubMed ID: 17395694
[TBL] [Abstract][Full Text] [Related]
17. A functional serine 118 phosphorylation site in estrogen receptor-alpha is required for down-regulation of gene expression by 17beta-estradiol and 4-hydroxytamoxifen.
Cheng J; Zhang C; Shapiro DJ
Endocrinology; 2007 Oct; 148(10):4634-41. PubMed ID: 17615152
[TBL] [Abstract][Full Text] [Related]
18. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
19. The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity.
Wang LH; Yang XY; Zhang X; Mihalic K; Xiao W; Farrar WL
Cancer Res; 2003 May; 63(9):2046-51. PubMed ID: 12727818
[TBL] [Abstract][Full Text] [Related]
20. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells.
Bramlett KS; Burris TP
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):27-34. PubMed ID: 12943742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
